The first case of vocal cord paralysis due to a mediastinal metastasis developing 16 years after the patient's endometrial cancer was treated by hysterectomy, external beam radiotherapy, and chemotherapy.
Delve into the efficacy and safety data for the antibody–drug conjugates currently approved by the US FDA across tumor types such as hematologic, genitourinary, and gynecologic cancers.
Completion axillary lymph node dissection can be avoided in patients with early-stage, node-negative breast cancer with one or two macrometastases, show phase 3 data.
Ovarian function suppression plays a key role in the management of breast cancer, but it comes with potentially impactful and long-lasting side effects. Counselling and proactive management of these should be considered an essential part of survivorship care.
Women with a new diagnosis of high-risk, locally advanced cervical cancer could benefit from the addition of pembrolizumab to standard chemoradiotherapy.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
The first case of vocal cord paralysis due to a mediastinal metastasis developing 16 years after the patient's endometrial cancer was treated by hysterectomy, external beam radiotherapy, and chemotherapy.
A case of extreme hypotension that could have been prevented or mitigated with awareness of the underlying hypothyroidism related to nivolumab treatment.
A woman developed sudden painless ecchymosis (bruising) of her breast, which was thought to be related to the radiotherapy she received for early-stage breast cancer a year and a half earlier.
Despite increased awareness and availability of genetic testing for hereditary breast and ovarian cancer (HBOC) syndrome for over 20 years, there is still significant underuse of cascade genetic testing among at-risk relatives. This scoping review …
More than 2 million women are diagnosed with breast cancer worldwide every year, and the estimated 5-year prevalence is almost 8 million cases. In Europe, breast cancer is the most frequently occurring cancer, accounting for about 15% of all new …
Breast cancer remains the most prevalent malignancy affecting women in the USA [ 1 ]. Despite improvements in survival and quality-of-life, a subset of patients develop metastatic disease, which continues to be a leading cause of cancer-related …
Currently, the main clinical application of liquid biopsy (LB) in breast cancer (BC) is the circulating tumor DNA (ctDNA)-based detection of treatment targets in metastatic or advanced disease. In this short review we focus on clinically relevant …
Take on interactive case studies with a focus on hematology. Each case has been prepared by renowned experts in the field and features knowledge-check questions with answers to help keep you and your practice up to date.
An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.
More than 2 million women are diagnosed with breast cancer worldwide every year, and the estimated 5-year prevalence is almost 8 million cases. In Europe, breast cancer is the most frequently occurring cancer, accounting for about 15% of all new …
Cervical cancer is the fourth most common malignancy in women worldwide [ 1 ]. With the introduction of cervical cancer screening programs, a decrease in the incidence of cervical cancer since 1970 was achieved. Nonetheless 4575 women were newly …
Antihormonal therapy is one of the mainstays in the treatment of estrogen receptor (ER) positive breast cancer, comprising 70–80% of all cases. During the last two decades, aromatase inhibitors (AIs) of the “third generation” pushed aside earlier …
HER2-positive (HER2+) breast cancer accounts for approximately 20% of all breast cancers and is responsible for a substantial proportion of deaths. In the early-stage (neo)adjuvant chemotherapy plus the anti-HER2 trastuzumab has consistently shown …
Delve into the efficacy and safety data for the antibody–drug conjugates currently approved by the US FDA across tumor types such as hematologic, genitourinary, and gynecologic cancers.
